- $1.28bn
- $1.36bn
- $1.15bn
- 75
- 75
- 37
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 897 | 892 | 1,132 | 1,296 | 1,147 |
Cost of Revenue | |||||
Gross Profit | 437 | 416 | 555 | 597 | 500 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 819 | 857 | 1,043 | 1,298 | 1,182 |
Operating Profit | 78.4 | 35.5 | 89.5 | -2.32 | -34.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 73.9 | 29.3 | 66 | -2.45 | -20.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 61.3 | 32.2 | 77.8 | 5.65 | -20.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 61.3 | 32.2 | 77.8 | 5.65 | -20.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 61.3 | 32.2 | 77.8 | 5.65 | -20.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.43 | 0.884 | 1.8 | 0.446 | -0.227 |